FDA accepts ImmunityBio’s application for Anktiva expansion By Investing.com

AI Summary

The FDA has accepted ImmunityBio's application to expand the use of its drug Anktiva, a significant step for the company in the oncology sector. This article discusses the potential impact on patient treatment and the market.